SeaWorld Entertainment SEAS 深 沪
已收盘 02-12 16:00:00 美东时间
50.30
0.000
0.00%
华盛通- 最 高--
- 今 开--
- 成交量 0股
- 最 低 --
- 昨 收 50.30
- 总市值 32.16亿
- 52周最高 68.195
- 市盈率 静 13.27
- 换手率 0.00%
- 52周最低 40.865
- 委 比 0.00%
- 总股本 6394.40万
- 历史最高 76.57
- 量 比 0
- 振 幅 0.00%
- 历史最低 6.75
- 每 手 1
- 风险率 0.00%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多SeaStar Medical to Report Second Quarter Financial Results on August 13, 2025
<p align="left"> Denver, August 7, 2025 (GLOBE NEWSWIRE) – SeaStar Medical Holding Corporation announced the release of its first quarter financial results on August 13, 2025, after the market close. A webcast and conference call will discuss financial results and business progress. The live webcast and replay can be accessed at [here]. The call replay number is 1 (609) 800-9909. SeaStar Medical is a healthcare company focused on transforming tre...
08-07 14:00
SeaStar Medical Reaches New Enrollment Milestone in NEUTRALIZE-AKI Pivotal Trial of SCD Therapy for Adult Patients with Acute Kidney Injury (AKI)
SeaStar Medical Holding Corporation announced that its NEUTRALIZE-AKI pivotal clinical trial has enrolled 125 of 200 anticipated patients and activated its 16<sup>th</sup> clinical trial site, Methodist Hospital Metropolitan of San Antonio, Texas. The trial is still on track to conduct an interim analysis of the first 100 patients in the third quarter of 2025. The interim analysis, conducted by an independent Data Safety Monitoring Review Board, ...
08-06 12:33
特朗普敲定“大萧条”以来最严厉关税，全球经济或迎严重需求冲击！
尽管市场对特朗普的关税方案反应平淡，但现实是：世界仍面临着自1930年代以来最严厉的美国关税，一场“严重的需求冲击”恐至。
08-01 20:13
SeaStar Medical Grows Customer Base and Expands QUELIMMUNE Surveillance Registry
SeaStar Medical has expanded itsQUELIMMUNE therapy to a Texas-based children’s hospital for treating ultra-rare pediatric AKI under FDA approval. Institutions participating in the SAVE Registry track outcomes for future analysis. CEO Eric Schlorff highlights progress in QUELIMMUNE adoption and registry data collection, alongside the NEUTRALIZE-AKI trial for adults, with 119 of 200 subjects enrolled. The trial assesses safety and efficacy in AKI p...
07-16 12:45
STAR OF THE SEAS OFFICIALLY JOINS ROYAL CARIBBEAN AS THE NEXT ICONIC VACATION
The ultimate family vacation has completed construction and is one step closer to its August debut in Port Canaveral (Orlando), Florida MIAMI, July 10, 2025 /PRNewswire/ -- Royal Caribbean k...
07-11 03:22
SeaStar Medical Announces Positive Nasdaq Listing Determination
DENVER, July 02, 2025 (GLOBE NEWSWIRE) - Medical Holding Corporation has confirmed compliance with Nasdaq listing requirements. The company is focusing on advancing QUELIMMUNE for pediatric AKI and developing the Selective Cytopheretic Device (SCD) therapy for adults with AKI in a pivotal trial.
07-02 20:25
SeaStar Medical Reports Update on Nasdaq Listing Status
SeaStar Medical has implemented several measures to regain compliance with Nasdaq listing standards, including a $4 million public offering, a $15 million stock purchase agreement, increased customer count for its FDA-approved QUELIMMUNE product, cost-cutting initiatives, and liability restructuring. The company believes these actions demonstrate compliance with Nasdaq's $2.5 million stockholders' equity requirement.QUELIMMUNE, designed for pedia...
06-25 12:05
INTRODUCING THE STAR OF STAR OF THE SEAS: ROYAL CARIBBEAN NAMES DIANA ROSS GODMOTHER
Diana Ross will take center stage as the godmother of the ultimate family vacation coming August 2025 MIAMI, June 5, 2025 /PRNewswire/ -- The ultimate family vacation is getting ready to set...
06-05 22:00
SeaStar Medical Announces CMS Coverage for Medicare and Medicaid Eligible Patients with Cardiorenal Syndrome Awaiting LVAD in Investigational Trial of SCD Therapy
SeaStar Medical announced that the U.S. Centers for Medicare & Medicaid Services (CMS) has agreed to reimburse certain expenses for Medicare and Medicaid patients enrolled in the NEUTRALIZE-CRS clinical trial. This marks the company's second CMS award for reimbursement, following the July 2024 approval for the NEUTRALIZE-AKI trial. CMS coverage is rare, with fewer than 100 awards granted annually, reflecting the potential life-saving impact of Se...
05-28 12:05
